Oncimmune Holdings plc (AIM:ONC)
London flag London · Delayed Price · Currency is GBP · Price in GBX
1.140
-0.050 (-4.20%)
Inactive · Last trade price on Mar 14, 2025

Oncimmune Holdings Company Description

Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally.

The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker.

It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.

Oncimmune Holdings plc
CountryUnited Kingdom
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees40
CEOMartin Gouldstone

Contact Details

Address:
1 Park Row
Leeds, LS1 5AB
United Kingdom
Websiteoncimmune.com

Stock Details

Ticker SymbolONC
ExchangeLondon Stock Exchange AIM
Fiscal YearSeptember - August
Reporting CurrencyGBP
ISIN NumberGB00BYQ94H38
SIC Code2835

Key Executives

NamePosition
Martin GouldstoneChief Executive Officer
Martin HudsonChief Financial Officer
Cléa RosenfeldHead of Investor Relations